205 related articles for article (PubMed ID: 36844736)
1. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study.
Chai Y; Jiang M; Wang Y; Liu Q; Lu Q; Tao Z; Wu Q; Yin W; Lu J; Pu J
Front Cardiovasc Med; 2023; 10():1021937. PubMed ID: 36844736
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract][Full Text] [Related]
7. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
[TBL] [Abstract][Full Text] [Related]
9. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
[TBL] [Abstract][Full Text] [Related]
10. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
Yin W; Wang Y; Wu Z; Ye Y; Zhou L; Xu S; Lin Y; Du Y; Yan T; Yang F; Zhang J; Liu Q; Lu J
Clin Cancer Res; 2022 Sep; 28(17):3677-3685. PubMed ID: 35713517
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
[TBL] [Abstract][Full Text] [Related]
14. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
Liu M; Zhou X
Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]